Fulcrum Therapeutics (NASDAQ:FULC) Director Alan Ezekowitz Sells 18,000 Shares of Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the sale, the director owned 10,927 shares in the company, valued at $39,883.55. This represents a 62.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Fulcrum Therapeutics Stock Down 1.9%

Fulcrum Therapeutics stock opened at $3.66 on Wednesday. The stock has a market cap of $243.87 million, a PE ratio of -3.18 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a 12-month low of $2.83 and a 12-month high of $15.74. The business’s 50-day moving average price is $5.57 and its two-hundred day moving average price is $8.18.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. As a group, analysts expect that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current year.

Institutional Trading of Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC lifted its holdings in Fulcrum Therapeutics by 21.9% during the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock worth $74,206,000 after buying an additional 1,180,111 shares during the period. Nantahala Capital Management LLC raised its position in shares of Fulcrum Therapeutics by 8.9% during the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after acquiring an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after acquiring an additional 1,589,000 shares during the last quarter. Braidwell LP lifted its stake in shares of Fulcrum Therapeutics by 1,294.7% in the fourth quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after acquiring an additional 2,841,734 shares during the period. Finally, Siren L.L.C. lifted its stake in shares of Fulcrum Therapeutics by 20.5% in the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 400,000 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FULC. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Citigroup cut Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on Fulcrum Therapeutics in a report on Tuesday, June 2nd. Finally, Piper Sandler lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $8.20.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.